InvestorsHub Logo
Followers 91
Posts 1956
Boards Moderated 0
Alias Born 07/31/2013

Re: None

Wednesday, 06/17/2015 12:44:18 AM

Wednesday, June 17, 2015 12:44:18 AM

Post# of 107
Company now Pulmatrix
We design and develop inhaled therapeutic products based on our proprietary dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. We are developing iSPERSE-based therapeutic candidates targeted at prevention and treatment of a range of respiratory diseases, targeting chronic obstructive pulmonary disease (COPD) and rare/orphan indications including cystic fibrosis (CF), and idiopathic pulmonary fibrosis (IPF).
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RTGN News